Representative Jefferson Shreve (R-Indiana) recently sold shares of Regeneron Pharmaceuticals, Inc. NASDAQ: REGN. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $15,001 and $50,000 in Regeneron Pharmaceuticals stock on April 7th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.
Representative Jefferson Shreve also recently made the following trade(s):
- Purchased $50,001 - $100,000 in shares of Chipotle Mexican Grill NYSE: CMG on 4/17/2025.
- Purchased $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Caterpillar NYSE: CAT on 4/17/2025.
- Sold $15,001 - $50,000 in shares of Lululemon Athletica NASDAQ: LULU on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Western Digital NASDAQ: WDC on 4/17/2025.
- Sold $15,001 - $50,000 in shares of Zoetis NYSE: ZTS on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Stryker NYSE: SYK on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Ross Stores NASDAQ: ROST on 4/17/2025.
Regeneron Pharmaceuticals Price Performance
Regeneron Pharmaceuticals stock traded down $3.98 during midday trading on Tuesday, reaching $571.65. The company had a trading volume of 502,893 shares, compared to its average volume of 773,495. Regeneron Pharmaceuticals, Inc. has a 12-month low of $520.50 and a 12-month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market capitalization of $62.50 billion, a P/E ratio of 14.93, a P/E/G ratio of 2.34 and a beta of 0.43. The firm's fifty day simple moving average is $610.85 and its 200-day simple moving average is $690.93.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter last year, the company earned $9.55 earnings per share. The firm's revenue for the quarter was down 3.7% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.
Regeneron Pharmaceuticals Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.62%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is 8.96%.
Institutional Trading of Regeneron Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in REGN. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $25,000. Rakuten Securities Inc. lifted its position in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares in the last quarter. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $28,000. E Fund Management Hong Kong Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares during the last quarter. Finally, Costello Asset Management INC acquired a new position in Regeneron Pharmaceuticals in the first quarter worth about $27,000. 83.31% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of analysts have recently commented on the company. Royal Bank of Canada dropped their price objective on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price objective for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating on the stock in a report on Wednesday, April 30th. The Goldman Sachs Group lowered their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Finally, Bank of America decreased their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, five have given a hold rating, eighteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $892.60.
Read Our Latest Stock Analysis on Regeneron Pharmaceuticals
About Representative Shreve
Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election.
Email editor@ballotpedia.org to notify us of updates to this biography.
Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive.
Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.
About Regeneron Pharmaceuticals
(
Get Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Read More
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
